Literature DB >> 15799238

The proteasome.

William S Dalton1.   

Abstract

The proteasome is an abundant multicatalytic enzyme complex present in the cytoplasm and nucleus of all eukaryotic cells. The primary function of the proteasome is to degrade proteins. While it was once thought to act primarily as a cellular "garbage disposal" that removed damaged or misfolded proteins from cells, the proteasome is now known to also remove various short-lived proteins that regulate the cell cycle, cell growth, and differentiation. By regulating the turnover of these proteins via timely degradation and recycling, the proteasome plays a critical role in the maintenance of cellular homeostasis. Substrates of the proteasome include cell-cycle regulators, signaling molecules, tumor suppressors, transcription factors, and antiapoptotic proteins; over 80% of all cellular proteins are recycled through the proteasome. This article discusses the structure and function of the proteasome, and its role in malignant cells and as a therapeutic target.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15799238     DOI: 10.1053/j.seminoncol.2004.10.012

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  16 in total

1.  On how mammary gland reprogramming metalloproteinases couple form with function.

Authors:  Bonnie F Sloane
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-07-01       Impact factor: 10.005

2.  Proteasomal chymotrypsin-like peptidase activity is required for essential functions of human monocyte-derived dendritic cells.

Authors:  Cord Naujokat; Carsten Berges; Alexandra Höh; Hubert Wieczorek; Dominik Fuchs; Jörg Ovens; Marion Miltz; Mahmoud Sadeghi; Gerhard Opelz; Volker Daniel
Journal:  Immunology       Date:  2006-11-03       Impact factor: 7.397

Review 3.  The potential of ixazomib, a second-generation proteasome inhibitor, in the treatment of multiple myeloma.

Authors:  Jason Brayer; Rachid Baz
Journal:  Ther Adv Hematol       Date:  2017-06-28

4.  Carfilzomib: a novel second-generation proteasome inhibitor.

Authors:  Meaghan L Khan; A Keith Stewart
Journal:  Future Oncol       Date:  2011-05       Impact factor: 3.404

5.  Reconstructing the Hsp90/Tau Machine.

Authors:  Umesh K Jinwal; John Koren; Chad A Dickey
Journal:  Curr Enzym Inhib       Date:  2013-01-01

6.  A phase I trial of bortezomib and interferon-α-2b in metastatic melanoma.

Authors:  Joseph Markowitz; Eric A Luedke; Valerie P Grignol; Erinn M Hade; Bonnie K Paul; Bethany L Mundy-Bosse; Taylor R Brooks; Thao-Vi Dao; Sri V Kondalasula; Gregory B Lesinski; Thomas Olencki; Kari L Kendra; William E Carson
Journal:  J Immunother       Date:  2014-01       Impact factor: 4.456

7.  Inhibition of glioblastoma cell proliferation, migration and invasion by the proteasome antagonist carfilzomib.

Authors:  Zammam Areeb; Stanley S Stylli; Thomas M B Ware; Nicole C Harris; Lipi Shukla; Ramin Shayan; Lucia Paradiso; Bo Li; Andrew P Morokoff; Andrew H Kaye; Rodney B Luwor
Journal:  Med Oncol       Date:  2016-04-20       Impact factor: 3.064

8.  Functional anthology of intrinsic disorder. 2. Cellular components, domains, technical terms, developmental processes, and coding sequence diversities correlated with long disordered regions.

Authors:  Slobodan Vucetic; Hongbo Xie; Lilia M Iakoucheva; Christopher J Oldfield; A Keith Dunker; Zoran Obradovic; Vladimir N Uversky
Journal:  J Proteome Res       Date:  2007-03-29       Impact factor: 4.466

9.  Effects of a novel proteasome inhibitor BU-32 on multiple myeloma cells.

Authors:  Sudipa S Roy; Nameer B Kirma; Bindu Santhamma; Rajeshwar R Tekmal; Joseph K Agyin
Journal:  Cancer Chemother Pharmacol       Date:  2014-04-12       Impact factor: 3.333

10.  BU-32: a novel proteasome inhibitor for breast cancer.

Authors:  Joseph K Agyin; Bindu Santhamma; Hareesh B Nair; Sudipa S Roy; Rajeshwar R Tekmal
Journal:  Breast Cancer Res       Date:  2009       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.